Highlights
- Surrogate indexes derived from the oral glucose tolerance test (OGTT), such as the Gutt and Cederholm indexes, demonstrate the highest predictive accuracy for type 2 diabetes (T2D) development over long-term follow-up.
- The Matsuda index showed the strongest correlation with the hyperinsulinemic-euglycemic clamp, the gold standard for measuring insulin sensitivity.
- Fasting insulin-based measures like HOMA-IR and QUICKI remain valuable but are less predictive than dynamic OGTT measures.
- Non-insulin-based indexes, specifically METS-IR, offer a viable screening alternative in clinical settings where insulin assays are unavailable.
The Challenge of Measuring Insulin Resistance in Clinical Practice
Insulin resistance (IR) is a fundamental pathophysiological driver of type 2 diabetes (T2D), cardiovascular disease, and metabolic syndrome. In the progression from normoglycemia to overt diabetes, a decrease in insulin sensitivity typically precedes clinical diagnosis by years. Therefore, accurately quantifying IR is a cornerstone of preventive medicine. However, the gold standard for measuring insulin sensitivity—the hyperinsulinemic-euglycemic clamp—is resource-intensive, technically demanding, and invasive, making it unsuitable for routine clinical practice or large-scale epidemiological studies.
To bridge this gap, various surrogate indexes have been developed. these range from simple fasting-state calculations like the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) to dynamic measures derived from the oral glucose tolerance test (OGTT). More recently, non-insulin-based indexes that utilize common parameters like triglycerides and body mass index (BMI) have emerged. Despite the proliferation of these tools, comparative data regarding their long-term predictive performance for T2D has remained limited, particularly in high-risk populations.
Methodology: A Comprehensive Comparison in a High-Risk Cohort
In a significant longitudinal cohort study, researchers evaluated the predictive performance of 18 different surrogate indexes of insulin resistance among 2,260 indigenous Americans from the Southwest United States. This population is historically at a higher risk for T2D, providing a robust environment for assessing metabolic markers. The study followed participants for up to 14.5 years, during which 509 incident cases of T2D were recorded.
The researchers utilized a dual-pronged approach to validation. First, they estimated the correlation coefficients (r) between each surrogate index and the glucose disposal rate (M-value) measured by the hyperinsulinemic-euglycemic clamp in a subset of 286 individuals. Second, they assessed the predictive performance of each index for incident T2D using hazard ratios (HR) per standard deviation and the area under the receiver operating curve (AUC). The 18 indexes were categorized into three groups: those requiring an OGTT, those requiring fasting insulin, and those requiring no insulin measurement.
The Hierarchy of Surrogate Indexes: Key Findings
The Superiority of OGTT-Derived Metrics
The findings clearly indicated that dynamic indexes derived from the OGTT are the most effective surrogates for predicting future diabetes. The Matsuda index exhibited the highest correlation with the M-value from the euglycemic clamp (r = 0.691), highlighting its strength as a physiological marker of insulin sensitivity. However, when it came to predicting the actual onset of T2D, the Gutt and Cederholm indexes emerged as the leaders, achieving the highest AUCs (0.728). These indexes outperformed all other categories, suggesting that the physiological response to a glucose challenge provides critical predictive data that fasting measures miss.
Fasting Insulin-Based Indexes: Practical but Limited
For clinicians who prefer fasting-state assessments, the Quantitative Insulin Sensitivity Check Index (QUICKI) and HOMA-IR were found to be the top performers. Both indexes showed identical correlation coefficients with the clamp (0.644) and identical predictive performance for T2D (AUC = 0.701). While these values are respectable, they are statistically inferior to the top-performing OGTT indexes. The primary advantage of QUICKI and HOMA-IR lies in their logistical simplicity, requiring only a single fasting blood draw, yet they may fail to capture the nuances of postprandial glucose handling.
Non-Insulin-Based Indexes: A Practical Alternative?
In many global healthcare settings, insulin assays are either unavailable or cost-prohibitive. The study evaluated several indexes that bypass insulin measurement entirely. Among these, the Metabolic Score for Insulin Resistance (METS-IR) and the Surrogate Predictive Index of Insulin Sensitivity (SPISE) performed best. METS-IR, which incorporates fasting glucose, triglycerides, and BMI, showed a correlation of 0.597 with the clamp and a predictive AUC of 0.688. While less precise than insulin-based measures, METS-IR provides a valuable tool for initial risk stratification in primary care settings.
Clinical Synthesis: Why Dynamic Testing Matters
The superior performance of OGTT-based indexes like Gutt and Cederholm is likely due to their ability to reflect both hepatic and peripheral insulin resistance. While fasting indexes primarily reflect hepatic insulin sensitivity and basal glucose production, OGTT-derived indexes capture the muscle’s ability to dispose of glucose under stimulated conditions. Since peripheral insulin resistance in the skeletal muscle is often the earliest detectable defect in the progression to T2D, the OGTT remains a vital diagnostic and predictive tool.
The study also highlighted that the predictive value of these indexes remained significant even after adjusting for traditional risk factors such as age, sex, and adiposity. This underscores that these surrogate markers are not merely proxies for obesity but are capturing distinct metabolic disturbances that lead to pancreatic beta-cell exhaustion and subsequent hyperglycemia.
Expert Commentary and Practical Applications
From a clinical standpoint, these results suggest a tiered approach to T2D risk assessment. For high-risk individuals, performing a standard 2-hour OGTT and calculating the Gutt or Matsuda index provides the highest resolution of their metabolic status. In routine primary care, HOMA-IR remains a standard but should be interpreted with the understanding that it may underestimate risk in patients with significant postprandial glycemic excursions. For resource-limited settings, the METS-IR index offers a scientifically validated method to identify at-risk patients using routine lipid panels and BMI calculations.
However, clinicians must also consider the limitations of this study. The cohort consisted of indigenous Americans, a population with a specific genetic and environmental risk profile. While the physiological principles of insulin resistance are universal, the specific cut-off values and performance of these indexes may vary across different ethnic groups. Further research is needed to validate these findings in more diverse global populations.
Conclusion: Refining Diabetes Prevention Strategies
The comparative analysis of 18 surrogate indexes confirms that dynamic, OGTT-based measures are the gold standard for predicting type 2 diabetes in clinical research and high-stakes clinical decision-making. While fasting insulin-based measures like HOMA-IR are easier to implement, they provide slightly lower predictive accuracy. The emergence of non-insulin-based markers like METS-IR provides an important safety net for metabolic screening when specialized assays are unavailable. Ultimately, the choice of index should be guided by the clinical context, but for the most accurate risk stratification, the dynamic response to glucose remains unparalleled.
References
- Vazquez L, Arreola EV, Nagul M, Krakoff J, Hanson RL. Comparing Surrogate Indexes for Insulin Resistance as Predictors of Type 2 Diabetes (T2D). The Journal of clinical endocrinology and metabolism. 2026. PMID: 41805838.
- Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462-1470.
- Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer model. Diabetes Care. 1998;21(12):2191-2192.
- Bello-Chavolla OY, et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. BMC Endocrine Disorders. 2018;18(1):30.
